Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
581
-
582
NatB-inactivation decreased Drk levels through its N-terminal sequences, which was regulated by the N-end rule E3 ubiquitin ligase POE/UBR4.
Published 2020“…<i>psid-D4</i> mutant clones (B) show similar levels of β-gal but decreased level of N-Drk-GFP in comparison to FRT control (A). …”
-
583
-
584
-
585
-
586
-
587
Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability.
Published 2015“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
-
588
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
589
-
590
-
591
-
592
-
593
-
594
-
595
Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia
Published 2016“…<i>Results</i>: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82–0.96). …”
-
596
-
597
-
598
-
599
-
600